119 related articles for article (PubMed ID: 16523821)
1. Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.
Fogarty GB; Bayne M; Bedford P; Bond R; Kannourakis G
Clin Oncol (R Coll Radiol); 2006 Mar; 18(2):155-6. PubMed ID: 16523821
[No Abstract] [Full Text] [Related]
2. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab.
Ollier L; Tieulie N; Sanderson F; Heudier P; Giordanengo V; Fuzibet JG; Nicand E
Ann Intern Med; 2009 Mar; 150(6):430-1. PubMed ID: 19293084
[No Abstract] [Full Text] [Related]
3. Immunosuppressive drug therapy as a potentiator of skin tumours in five patients with lymphoma.
Hill BH
Australas J Dermatol; 1976 Aug; 17(2):46-8. PubMed ID: 1037366
[No Abstract] [Full Text] [Related]
4. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
Orouji A; Goerdt S; Utikal J; Leverkus M
Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
[No Abstract] [Full Text] [Related]
5. Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
Fujii M; Iwasaki T; Takahashi I; Kishiyama K; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
J Dermatol; 2015 Mar; 42(3):338-9. PubMed ID: 25580575
[No Abstract] [Full Text] [Related]
6. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy.
Tsutsumi Y; Ichiki K; Shiratori S; Kawamura T; Tanaka J; Asaka M; Imamura M; Masauzi N
Int J Lab Hematol; 2009 Aug; 31(4):468-70. PubMed ID: 18294236
[No Abstract] [Full Text] [Related]
7. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab.
Chang H; Yeh HC; Su YC; Lee MH
J Chin Med Assoc; 2008 Nov; 71(11):579-82. PubMed ID: 19015057
[TBL] [Abstract][Full Text] [Related]
8. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.
De Simone C; Guerriero C; Guidi B; Rotoli M; Venier A; Tartaglione R
Eur J Dermatol; 1998 Mar; 8(2):114-5. PubMed ID: 9649662
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient.
Unluturk U; Aksoy S; Yonem O; Bayraktar Y; Tekuzman G
World J Gastroenterol; 2006 Mar; 12(12):1978-9. PubMed ID: 16610013
[No Abstract] [Full Text] [Related]
10. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Yang H; Rosove MH; Figlin RA
Am J Hematol; 1999 Dec; 62(4):247-50. PubMed ID: 10589082
[TBL] [Abstract][Full Text] [Related]
11. [Combination treatment of a cutaneous non-Hodgkin's lymphoma with rituximab and polychemotherapy].
Reinerth G; Bruch-Gerharz D; Kruse R; Bernhardt A; Schulte KW
Hautarzt; 2007 Apr; 58(4):295-7. PubMed ID: 17333026
[No Abstract] [Full Text] [Related]
12. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis.
Ramamoorthy SK; Marangolo M; Durrant E; Akima S; Gottlieb DJ
Leuk Lymphoma; 2006 Apr; 47(4):747-50. PubMed ID: 16690535
[No Abstract] [Full Text] [Related]
13. Malignancies after rituximab treatment: just coincidence or more?
Aksoy S; Arslan C; Harputluoglu H; Dizdar O; Altundag K
J BUON; 2011; 16(1):112-5. PubMed ID: 21674860
[TBL] [Abstract][Full Text] [Related]
14. Delayed-onset neutropenia associated with rituximab therapy.
Chaiwatanatorn K; Lee N; Grigg A; Filshie R; Firkin F
Br J Haematol; 2003 Jun; 121(6):913-8. PubMed ID: 12786803
[TBL] [Abstract][Full Text] [Related]
15. [Generalized lymphadenopathy and B symptoms].
Nägelein R
Internist (Berl); 2006 Sep; 47(9):974; author reply 974. PubMed ID: 17245841
[No Abstract] [Full Text] [Related]
16. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
17. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
18. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
Ezra N; Hamid O; Behroozan D
Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
[No Abstract] [Full Text] [Related]
19. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
Rashidi A; Oak E; Bartlett NL
Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
[No Abstract] [Full Text] [Related]
20. (18)F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib.
Nguyen BD
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):64-6. PubMed ID: 26251366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
